PGEN Stock — Precigen, Inc.

Precigen, Inc. (PGEN)

Updated October 16, 2026.

PGEN is a Stock. Total return is -73.0% over the past 13.2 years, 534.9 points behind SPY at 461.9%.

Precigen is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company's therapeutic platforms include AdenoVerse, which uses proprietary adenovectors for gene delivery, and UltraCAR-T, which provides chimeric antigen receptor T cell therapies; multiple programs based on these platforms are in Phase 1 through Phase 2 clinical trials. Precigen does not currently have an established distribution schedule, making it suited primarily for growth-oriented investors rather than those seeking current income.

PGEN performance versus SPY

Price and return data through 2026-10-16.

Total return is -73.0% over the past 13.2 years, 534.9 points behind SPY at 461.9%. Over the past year its total return — price change plus distributions reinvested — is 83.0%. Its deepest 1-year drawdown was 40.5%.

PGEN key facts

Asset type

Stock

Asset class

Equity

Inception date

08/08/2013

Distribution frequency

None

Last close

$6.38 (as of 2026-10-16)

Market cap

$2,286,055,052

Average volume

5477482.0

Beta

0.919

Payout ratio

0.0%

Forward P/E

16.8919

EPS

$-1.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PGEN risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 40.5%.

Who may consider PGEN — and who may not

It is a weaker fit for investors who need monthly cash flow (PGEN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PGEN

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions